We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Newly Identified Genes May Help to Screen and Treat Individuals with Hearing Loss

By LabMedica International staff writers
Posted on 17 May 2022

A massive genome-wide association study (GWAS) identified 10 novel gene loci associated with hearing loss, which may aid in screening and treating the disorder. More...

Hearing loss is one of the top contributors to years lived with disability and is a risk factor for developing dementia. Hearing loss is a major medical problem worldwide with an estimated 2.4 billion individuals expected to have some form of hearing loss by the year 2050.

Molecular evidence on the cellular origins of hearing loss in humans is growing. In this regard, investigators at King's College London (United Kingdom) and colleagues at Karolinska Institute (Stockholm, Sweden) and Erasmus University (Rotterdam, Netherlands) performed a genome-wide association meta-analysis of clinically diagnosed and self-reported hearing impairment on 723,266 individuals. The study comprised 147,997 affected individuals and 575,269 control subjects including 60,941 affected individuals that were not included in a previously published GWAS meta-analysis.

Results of the meta-analysis revealed 48 genes linked to hearing loss, including 10 novel variants newly linked to hearing.

Contributing author Dr. Frances Williams, professor of genomic epidemiology at King's College London, said, "Our findings identify 10 genes newly linked with hearing loss. This study points to genes we could target for screening purposes, drug development. and even gene therapy in the future. This study provides a solid foundation for ultimately improving therapies against hearing loss."

The study was published in the May 16, 2022, online edition of the American Journal of Human Genetics.

Related Links:
King's College London 
Karolinska Institute 
Erasmus University 

 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.